DUBLIN--(BUSINESS WIRE)--The "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Extensive-Stage Small Cell Lung Cancer (ESCLC): Overview
Extensive stage small cell lung cancer (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months. The liver, adrenal glands, and bone are also common sites of metastasis.
Though extensive-stage small cell lung cancer cannot be cured and has a poor prognosis, it may respond to chemotherapy and newer treatments. Because the cancer has spread, the main treatment for extensive stage SCLC is chemotherapy. Common chemo drugs used for ESCLC are: carboplatin and cisplatin. Other therapies used to treat ESCLS include: immunotherapy and radiation therapy.
"Extensive-Stage Small Cell Lung Cancer (ESCLC)- Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
A detailed picture of the Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape is provided which includes the disease overview and Extensive-Stage Small Cell Lung Cancer (ESCLC) treatment guidelines. The assessment part of the report embraces, in depth Extensive-Stage Small Cell Lung Cancer (ESCLC) commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Extensive-Stage Small Cell Lung Cancer (ESCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Extensive-Stage Small Cell Lung Cancer (ESCLC) R&D. The therapies under development are focused on novel approaches to treat/improve Extensive-Stage Small Cell Lung Cancer (ESCLC).
Extensive-Stage Small Cell Lung Cancer (ESCLC) Emerging Drugs Chapters
This segment of the Extensive-Stage Small Cell Lung Cancer (ESCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Extensive-Stage Small Cell Lung Cancer (ESCLC) Emerging Drugs
- BMS-986012: Bristol-Myers Squibb
BMS-986012 is a human antifucosyl-GM1 antibody. It is under phase 2 of clinical trials along with Carboplatin and Etoposide for the treatment of ESCLC.
- LY 2510924: Eli Lilly and Company
LY-2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY-2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation.
Extensive-Stage Small Cell Lung Cancer (ESCLC): Therapeutic Assessment
This segment of the report provides insights about the different Extensive-Stage Small Cell Lung Cancer (ESCLC) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Extensive-Stage Small Cell Lung Cancer (ESCLC)
There are approx. 10+ key companies which are developing the therapies for Extensive-Stage Small Cell Lung Cancer (ESCLC). The companies which have their Extensive-Stage Small Cell Lung Cancer (ESCLC) drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Bristol-Myers Squibb and others.
The report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Parenteral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Peptides
- Polymer
- Gene Therapy
- Monoclonal antibodies
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Extensive-Stage Small Cell Lung Cancer (ESCLC): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Extensive-Stage Small Cell Lung Cancer (ESCLC) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Extensive-Stage Small Cell Lung Cancer (ESCLC) drugs.
Extensive-Stage Small Cell Lung Cancer (ESCLC) Report Insights
- Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Extensive-Stage Small Cell Lung Cancer (ESCLC) Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Bristol-Myers Squibb
- Eli Lilly and Company
- Henlix Biotech
- CSPC ZhongQi Pharmaceutical Technology
Key Products
- BMS-986012
- LY 2510924
- Serplulimab (HLX-10)
- SYHA-1807
- AL 3810
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7xa3cy
